Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas

<p>Abstract</p> <p>Background</p> <p>Local control rates are poor in the treatment of pancreatic cancer. We investigated the role of hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses of external beam radi...

Full description

Bibliographic Details
Main Authors: Lominska Chris E, Unger Keith, Nasr Nadim M, Haddad Nadim, Gagnon Greg
Format: Article
Language:English
Published: BMC 2012-05-01
Series:Radiation Oncology
Subjects:
Online Access:http://www.ro-journal.com/content/7/1/74
_version_ 1818370433569783808
author Lominska Chris E
Unger Keith
Nasr Nadim M
Haddad Nadim
Gagnon Greg
author_facet Lominska Chris E
Unger Keith
Nasr Nadim M
Haddad Nadim
Gagnon Greg
author_sort Lominska Chris E
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Local control rates are poor in the treatment of pancreatic cancer. We investigated the role of hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses of external beam radiation therapy.</p> <p>Methods</p> <p>All patients treated with SBRT for pancreatic adenocarcinoma at Georgetown University from June 2002 through July 2007 were examined. Eligible patients had prior external beam radiation therapy to the pancreas. Treatment parameters and clinical and radiographic follow-up were evaluated.</p> <p>Results</p> <p>Twenty-eight patients were identified who received SBRT after a median prior external beam radiotherapy dose of 50.4 Gy. The median patient age was 63 years old and the median follow-up was 5.9 months. Twelve of fourteen (85.7%) evaluable patients were free from local progression, with three partial responses and nine patients with stable disease. Toxicity consisted of one case of acute Grade II nausea/vomiting, and two cases of Grade III late GI toxicity. The median overall survival was 5.9 months, with 18% survival and 70% freedom from local progression at one year.</p> <p>Conclusions</p> <p>Hypofractionated SBRT reirradiation of localized pancreatic cancer is a well-tolerated treatment. Most patients are free from local progression, albeit with limited follow-up, but overall survival remains poor.</p>
first_indexed 2024-12-13T23:39:40Z
format Article
id doaj.art-43b36ce205234209a822332580bfa12f
institution Directory Open Access Journal
issn 1748-717X
language English
last_indexed 2024-12-13T23:39:40Z
publishDate 2012-05-01
publisher BMC
record_format Article
series Radiation Oncology
spelling doaj.art-43b36ce205234209a822332580bfa12f2022-12-21T23:27:11ZengBMCRadiation Oncology1748-717X2012-05-01717410.1186/1748-717X-7-74Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreasLominska Chris EUnger KeithNasr Nadim MHaddad NadimGagnon Greg<p>Abstract</p> <p>Background</p> <p>Local control rates are poor in the treatment of pancreatic cancer. We investigated the role of hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses of external beam radiation therapy.</p> <p>Methods</p> <p>All patients treated with SBRT for pancreatic adenocarcinoma at Georgetown University from June 2002 through July 2007 were examined. Eligible patients had prior external beam radiation therapy to the pancreas. Treatment parameters and clinical and radiographic follow-up were evaluated.</p> <p>Results</p> <p>Twenty-eight patients were identified who received SBRT after a median prior external beam radiotherapy dose of 50.4 Gy. The median patient age was 63 years old and the median follow-up was 5.9 months. Twelve of fourteen (85.7%) evaluable patients were free from local progression, with three partial responses and nine patients with stable disease. Toxicity consisted of one case of acute Grade II nausea/vomiting, and two cases of Grade III late GI toxicity. The median overall survival was 5.9 months, with 18% survival and 70% freedom from local progression at one year.</p> <p>Conclusions</p> <p>Hypofractionated SBRT reirradiation of localized pancreatic cancer is a well-tolerated treatment. Most patients are free from local progression, albeit with limited follow-up, but overall survival remains poor.</p>http://www.ro-journal.com/content/7/1/74SBRTReirradiationRadiotherapyPancreatic cancer
spellingShingle Lominska Chris E
Unger Keith
Nasr Nadim M
Haddad Nadim
Gagnon Greg
Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
Radiation Oncology
SBRT
Reirradiation
Radiotherapy
Pancreatic cancer
title Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
title_full Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
title_fullStr Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
title_full_unstemmed Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
title_short Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
title_sort stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas
topic SBRT
Reirradiation
Radiotherapy
Pancreatic cancer
url http://www.ro-journal.com/content/7/1/74
work_keys_str_mv AT lominskachrise stereotacticbodyradiationtherapyforreirradiationoflocalizedadenocarcinomaofthepancreas
AT ungerkeith stereotacticbodyradiationtherapyforreirradiationoflocalizedadenocarcinomaofthepancreas
AT nasrnadimm stereotacticbodyradiationtherapyforreirradiationoflocalizedadenocarcinomaofthepancreas
AT haddadnadim stereotacticbodyradiationtherapyforreirradiationoflocalizedadenocarcinomaofthepancreas
AT gagnongreg stereotacticbodyradiationtherapyforreirradiationoflocalizedadenocarcinomaofthepancreas